Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin:a randomized, double-blind, placebo-controlled trial
| Data(s) |
01/09/2010
|
|---|---|
| Resumo |
To evaluate the dose-response relationship of lixisenatide (AVE0010), a glucagon-like peptide-1 (GLP-1) receptor agonist, in metformin-treated patients with Type 2 diabetes. |
| Identificador | |
| Idioma(s) |
eng |
| Direitos |
info:eu-repo/semantics/restrictedAccess |
| Fonte |
Ratner , R E , Rosenstock , J , Boka , G , DRI6012 Study Investigators & Lyons , T 2010 , ' Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin : a randomized, double-blind, placebo-controlled trial ' Diabetic Medicine , vol 27 , no. 9 , pp. 1024-32 . DOI: 10.1111/j.1464-5491.2010.03020.x |
| Palavras-Chave | #Adult #Aged #Blood Glucose #Diabetes Mellitus, Type 2 #Dose-Response Relationship, Drug #Double-Blind Method #Drug Resistance #Female #Hemoglobin A, Glycosylated #Humans #Hypoglycemic Agents #Male #Metformin #Middle Aged #Peptides #Placebos #Receptors, Glucagon |
| Tipo |
article |
